Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
4DMedical Ltd ( (AU:4DX) ) has provided an update.
4DMedical Ltd addressed a query from the ASX regarding the impairment assessment of its intangible assets, following its acquisition of Imbio Inc. The company outlined its assumptions and evidence provided to auditors, emphasizing its commitment to achieving forecasted revenue growth through commercial activities and partnerships. The company aims to secure an unqualified audit opinion in future financial statements by enhancing its revenue generation strategies.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.25 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd operates in the healthcare industry, focusing on innovative medical imaging solutions. The company specializes in developing advanced lung imaging technologies, including FDA-approved AI technology solutions and cloud-based imaging platforms, aimed at improving lung health diagnostics.
Average Trading Volume: 8,215,642
Technical Sentiment Signal: Buy
Current Market Cap: A$822.7M
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.